Učitavanje...
B cells as biomarkers: predicting immune checkpoint therapy adverse events
Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-...
Spremljeno u:
| Izdano u: | J Clin Invest |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Clinical Investigation
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5785256/ https://ncbi.nlm.nih.gov/pubmed/29309049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI99036 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|